{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:17:05Z","timestamp":1788675425504,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,19]]},"DOI":"10.7759\/cureus.109208","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:20:35Z","timestamp":1779214835000},"source":"Crossref","is-referenced-by-count":1,"title":["Drug-Free Remission of VEXAS Syndrome Without Stem Cell Transplantation"],"prefix":"10.7759","author":[{"given":"Jenny","family":"Warren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Smylie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardyth","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck DB","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA, et al.. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020, 383:2628-38. 10.1056\/NEJMoa2026834","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2157262","article-title":"An update on VEXAS syndrome","volume":"19","author":"Al-Hakim A","year":"2023","unstructured":"Al-Hakim A, Savic S. An update on VEXAS syndrome. Expert Rev Clin Immunol. 2023, 19:203-15. 10.1080\/1744666X.2023.2157262","journal-title":"Expert Rev Clin Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.678927","article-title":"Case report: VEXAS syndrome: from mild symptoms to life-threatening macrophage activation syndrome","volume":"12","author":"Staels F","year":"2021","unstructured":"Staels F, Betrains A, Woei-A-Jin FJ, et al.. Case report: VEXAS syndrome: from mild symptoms to life-threatening macrophage activation syndrome. Front Immunol. 2021, 12:678927. 10.3389\/fimmu.2021.678927","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20805","article-title":"Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients","volume":"186","author":"Georgin-Lavialle S","year":"2022","unstructured":"Georgin-Lavialle S, Terrier B, Guedon AF, et al.. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol. 2022, 186:564-74. 10.1111\/bjd.20805","journal-title":"Br J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.05.014","article-title":"Adult-onset autoinflammation caused by somatic mutations in UBA1: a\u00a0Dutch case series of patients with VEXAS","volume":"149","author":"van der Made CI","year":"2022","unstructured":"van der Made CI, Potjewijd J, Hoogstins A, et al.. Adult-onset autoinflammation caused by somatic mutations in UBA1: a\u00a0Dutch case series of patients with VEXAS. J Allergy Clin Immunol. 2022, 149:432-439.e4. 10.1016\/j.jaci.2021.05.014","journal-title":"J Allergy Clin Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010177","article-title":"Therapeutic options in VEXAS syndrome: insights from a retrospective series","volume":"137","author":"Bourbon E","year":"2021","unstructured":"Bourbon E, Heiblig M, Gerfaud Valentin M, et al.. Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood. 2021, 137:3682-4. 10.1182\/blood.2020010177","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004749","article-title":"Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience","volume":"6","author":"Diarra A","year":"2022","unstructured":"Diarra A, Duployez N, Fournier E, et al.. Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Adv. 2022, 6:998-1003. 10.1182\/bloodadvances.2021004749","journal-title":"Blood Adv"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225640","article-title":"Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX","volume":"83","author":"Hadjadj J","year":"2024","unstructured":"Hadjadj J, Nguyen Y, Mouloudj D, et al.. Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX. Ann Rheum Dis. 2024, 83:1358-67. 10.1136\/ard-2024-225640","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1644404","article-title":"VEXAS: a review of current understandings and emerging treatment strategies","volume":"16","author":"Holden R","year":"2025","unstructured":"Holden R, Jeelal Y, McLean-Tooke A, Pathmanathan K, Nolan D. VEXAS: a review of current understandings and emerging treatment strategies. Front Immunol. 2025, 16:1644404. 10.3389\/fimmu.2025.1644404","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead425","article-title":"Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome","volume":"63","author":"Maeda A","year":"2024","unstructured":"Maeda A, Tsuchida N, Uchiyama Y, et al.. Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome. Rheumatology (Oxford). 2024, 63:2056-64. 10.1093\/rheumatology\/kead425","journal-title":"Rheumatology (Oxford)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/art.43327","article-title":"Clinical manifestations of VEXAS syndrome across a broad spectrum of UBA1 mutation burden","volume":"78","author":"Anderson M","year":"2026","unstructured":"Anderson M, Ercelen D, Richardson A, et al.. Clinical manifestations of VEXAS syndrome across a broad spectrum of UBA1 mutation burden. Arthritis Rheumatol. 2026, 78:223-30. 10.1002\/art.43327","journal-title":"Arthritis Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-03003-x","article-title":"Dynamic monitoring of UBA1 somatic mutations in patients with relapsing polychondritis","volume":"19","author":"Duan S","year":"2024","unstructured":"Duan S, Luo H, Wang Y, et al.. Dynamic monitoring of UBA1 somatic mutations in patients with relapsing polychondritis. Orphanet J Rare Dis. 2024, 19:1. 10.1186\/s13023-023-03003-x","journal-title":"Orphanet J Rare Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05611-w","article-title":"VEXAS syndrome: complete molecular remission after hypomethylating therapy","volume":"103","author":"Sockel K","year":"2024","unstructured":"Sockel K, G\u00f6tze K, Ganster C, et al.. VEXAS syndrome: complete molecular remission after hypomethylating therapy. Ann Hematol. 2024, 103:993-7. 10.1007\/s00277-023-05611-w","journal-title":"Ann Hematol"},{"key":"ref14","article-title":"An atypical case of VEXAS syndrome: the diagnostic challenge of an acquired autoinflammatory disorder","volume":"51 (Suppl 1)","author":"Melanson J","year":"2024","unstructured":"Melanson J, Vantomme K, Milne A. An atypical case of VEXAS syndrome: the diagnostic challenge of an acquired autoinflammatory disorder. J Rheumatol. 2024, 51 (Suppl 1):43-98.","journal-title":"J Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024028133","article-title":"Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX","volume":"146","author":"Jachiet V","year":"2025","unstructured":"Jachiet V, Kosmider O, Beydon M, et al.. Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX. Blood. 2025, 146:1450-61. 10.1182\/blood.2024028133","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/448825-drug-free-remission-of-vexas-syndrome-without-stem-cell-transplantation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:20:36Z","timestamp":1779214836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/448825-drug-free-remission-of-vexas-syndrome-without-stem-cell-transplantation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.109208","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,19]]}}}